Nephropathic subjects with impaired immune responses show dramatically high infection rates of coronavirus disease 2019 (COVID-19). This work evaluated the ability to acquire and maintain protective antibodies over time in 26 hemodialysis patients and 21 kidney transplant recipients. The subjects were followed-up through quantitative determination of circulating SARS-CoV-2 S1/S2 IgG and neutralizing antibodies in the 6-month period after clinical and laboratory recovery. A group of 143 healthcare workers with no underlying chronic pathologies or renal diseases recovered from COVID was also evaluated. In both dialysis and transplanted patients, antibody titers reached a zenith around the 3rd month, and then a decline occurred on average between the 270th and 300th day. Immunocompromised patients who lost antibodies around the 6th month were more common than non-renal subjects, although the difference was not significant (38.5% vs. 26.6%). Considering the decay of antibody levels below the positivity threshold (15 AU/mL) as “failure”, a progressive loss of immunisation was found in the overall population starting 6 months after recovery. A longer overall antibody persistence was observed in severe forms of COVID-19 (p = 0.0183), but within each group, given the small number of patients, the difference was not significant (dialysis: p = 0.0702; transplant: p = 0.1899). These data suggest that immunocompromised renal patients recovered from COVID-19 have weakened and heterogeneous humoral responses that tend to decay over time. Despite interindividual variability, an association emerged between antibody persistence and clinical severity, similar to the subjects with preserved immune function.

Persistence of antibody responses to the sars-cov-2 in dialysis patients and renal transplant recipients recovered from covid-19 / Cappuccilli M.; Bruno P.F.; Spazzoli A.; Righini M.; Flachi M.; Semprini S.; Grumiro L.; Marino M.M.; Schiavone P.; Fabbri E.; Fantini M.; Buscaroli A.; Rigotti A.; La Manna G.; Sambri V.; Mosconi G.. - In: PATHOGENS. - ISSN 2076-0817. - ELETTRONICO. - 10:10(2021), pp. 1289.1-1289.15. [10.3390/pathogens10101289]

Persistence of antibody responses to the sars-cov-2 in dialysis patients and renal transplant recipients recovered from covid-19

Cappuccilli M.;Bruno P. F.;Spazzoli A.;Righini M.;Flachi M.;Semprini S.;Schiavone P.;Buscaroli A.;La Manna G.;Sambri V.;
2021

Abstract

Nephropathic subjects with impaired immune responses show dramatically high infection rates of coronavirus disease 2019 (COVID-19). This work evaluated the ability to acquire and maintain protective antibodies over time in 26 hemodialysis patients and 21 kidney transplant recipients. The subjects were followed-up through quantitative determination of circulating SARS-CoV-2 S1/S2 IgG and neutralizing antibodies in the 6-month period after clinical and laboratory recovery. A group of 143 healthcare workers with no underlying chronic pathologies or renal diseases recovered from COVID was also evaluated. In both dialysis and transplanted patients, antibody titers reached a zenith around the 3rd month, and then a decline occurred on average between the 270th and 300th day. Immunocompromised patients who lost antibodies around the 6th month were more common than non-renal subjects, although the difference was not significant (38.5% vs. 26.6%). Considering the decay of antibody levels below the positivity threshold (15 AU/mL) as “failure”, a progressive loss of immunisation was found in the overall population starting 6 months after recovery. A longer overall antibody persistence was observed in severe forms of COVID-19 (p = 0.0183), but within each group, given the small number of patients, the difference was not significant (dialysis: p = 0.0702; transplant: p = 0.1899). These data suggest that immunocompromised renal patients recovered from COVID-19 have weakened and heterogeneous humoral responses that tend to decay over time. Despite interindividual variability, an association emerged between antibody persistence and clinical severity, similar to the subjects with preserved immune function.
2021
Persistence of antibody responses to the sars-cov-2 in dialysis patients and renal transplant recipients recovered from covid-19 / Cappuccilli M.; Bruno P.F.; Spazzoli A.; Righini M.; Flachi M.; Semprini S.; Grumiro L.; Marino M.M.; Schiavone P.; Fabbri E.; Fantini M.; Buscaroli A.; Rigotti A.; La Manna G.; Sambri V.; Mosconi G.. - In: PATHOGENS. - ISSN 2076-0817. - ELETTRONICO. - 10:10(2021), pp. 1289.1-1289.15. [10.3390/pathogens10101289]
Cappuccilli M.; Bruno P.F.; Spazzoli A.; Righini M.; Flachi M.; Semprini S.; Grumiro L.; Marino M.M.; Schiavone P.; Fabbri E.; Fantini M.; Buscaroli A.; Rigotti A.; La Manna G.; Sambri V.; Mosconi G.
File in questo prodotto:
File Dimensione Formato  
Cappuccilli M et al_Pathogens 2021.pdf

accesso aperto

Descrizione: Cappuccilli M et al_Pathogens 2021
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 2.31 MB
Formato Adobe PDF
2.31 MB Adobe PDF Visualizza/Apri
pathogens-10-01289-s001.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Altra tipologia di licenza compatibile con Open Access
Dimensione 458.49 kB
Formato Zip File
458.49 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/837695
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact